NCT06027684 Intensive Care Decision-making, Survival and Dying Well
| NCT ID | NCT06027684 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Manchester |
| Condition | Critical Illness |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2023-10-02 |
| Primary Completion | 2025-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2023-10-02 with a primary completion date of 2025-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to investigate how the experiences of intensive care patients and their end-of-life wishes affect their willingness to accept intensive care treatment at different chances of survival. The main questions it aims to answer are: * What can ICU survivors' experiences of ICU treatment tell us about what it would be like to die whilst receiving ICU treatment? * How do ICU survivors' reflections about what it might be like to die on ICU relate to their own preferences for their end-of-life care? * What chance of survival would make ICU survivors willing to go through ICU treatment again, in light of the fact that the alternative chance is dying whilst experiencing ICU treatment? * How does the possibility of reduction in health-related quality of life and functional decline as a result of critical illness impact ICU survivors' willingness to accept ICU treatment again? Participating in this study will involve filling out a questionnaire and then taking part in an interview. Participants will be recruited through ICU review clinics and ICU steps groups. The study will last for two years and will be conducted at locations convenient to the participants or via zoom.
Eligibility Criteria
Inclusion Criteria: * The principle inclusion criteria are being 18 years or older and having previously been a patient on an intensive care/critical care unit in the past. * Being willing to talk about experiences of intensive care treatment, end-of-life wishes, and the context (chances of survival/functional decline) which would make intensive care treatments acceptable and being willing to either meet in person or have access to a computer, tablet or mobile phone with video and a stable internet connection (for a Zoom conversation) are also inclusion criteria. Exclusion Criteria: * The exclusion criteria are being under the age of 18, having had a planned admission to an intensive care/critical care unit (e.g. after an elective operation), being unable to consent to participate in the research and having a significant language barrier (as there is no available funding to pay for translation).
Contact & Investigator
Thomas M Donaldson, MB/BChir
PRINCIPAL INVESTIGATOR
University of Manchester
Frequently Asked Questions
Who can join the NCT06027684 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Critical Illness. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06027684 currently recruiting?
Yes, NCT06027684 is actively recruiting participants. Contact the research team at thomas.donaldson-2@postgrad.manchester.ac.uk for enrollment information.
Where is the NCT06027684 trial being conducted?
This trial is being conducted at Manchester, United Kingdom.
Who is sponsoring the NCT06027684 clinical trial?
NCT06027684 is sponsored by University of Manchester. The principal investigator is Thomas M Donaldson, MB/BChir at University of Manchester. The trial plans to enroll 50 participants.